Literature DB >> 27440178

Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.

Taku Fujimura1, Yumi Kambayashi1, Sadanori Furudate1, Aya Kakizaki1, Takanori Hidaka1, Takahiro Haga1, Akira Hashimoto1, Ryo Morimoto2, Setsuya Aiba1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27440178     DOI： 10.1111/1346-8138.13532

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  16 in total

Review 1.  Melanoma and Immune Checkpoint Inhibitors.

Authors:  Masutaka Furue; Takamichi Ito; Naoko Wada; Maiko Wada; Takafumi Kadono; Hiroshi Uchi
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

2.  A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency.

Authors:  Yozo Sato; Yosuke Tanaka; Mitsunori Hino; Masahiro Seike; Akihiko Gemma
Journal:  Respir Med Case Rep       Date:  2019-01-28

Review 3.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

Review 4.  Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review.

Authors:  Pedro Iglesias; Juan Cristóbal Sánchez; Juan José Díez
Journal:  Pituitary       Date:  2021-03-24       Impact factor: 4.107

5.  Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.

Authors:  Kazuhiko Takaya; Miwa Sonoda; Ayako Fuchigami; Toru Hiyoshi
Journal:  Intern Med       Date:  2017-08-21       Impact factor: 1.271

Review 6.  Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer.

Authors:  Taku Fujimura; Yumi Kambayashi; Yasuhiro Fujisawa; Takanori Hidaka; Setsuya Aiba
Journal:  Front Oncol       Date:  2018-01-23       Impact factor: 6.244

7.  Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma.

Authors:  Taku Fujimura; Takanori Hidaka; Yumi Kambayashi; Sadanori Furudate; Aya Kakizaki; Hisayuki Tono; Akira Tsukada; Takahiro Haga; Akira Hashimoto; Ryo Morimoto; Takuhiro Yamaguchi; Tadao Takano; Setsuya Aiba
Journal:  Oncotarget       Date:  2017-04-13

Review 8.  Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review.

Authors:  Nobumasa Ohara; Kazumasa Ohashi; Toshiya Fujisaki; Chiyumi Oda; Yohei Ikeda; Yuichiro Yoneoka; Takehisa Hashimoto; Go Hasegawa; Kazuo Suzuki; Toshinori Takada
Journal:  Intern Med       Date:  2017-11-20       Impact factor: 1.271

9.  Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.

Authors:  Taku Fujimura; Yota Sato; Kayo Tanita; Yumi Kambayashi; Atsushi Otsuka; Yasuhiro Fujisawa; Koji Yoshino; Shigeto Matsushita; Takeru Funakoshi; Hiroo Hata; Yuki Yamamoto; Hiroshi Uchi; Yumi Nonomura; Ryota Tanaka; Megumi Aoki; Keisuke Imafuku; Hisako Okuhira; Sadanori Furudate; Takanori Hidaka; Setsuya Aiba
Journal:  Oncotarget       Date:  2018-02-15

10.  Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy.

Authors:  Alison Taylor; Christopher E Rudd
Journal:  J Immunol Sci       Date:  2019-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.